Catalyst Wire Dossier Catalyst Wire Dossier

Eribulin (Halaven)

eribulin mesylate · Eisai
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Eribulin (Halaven), covering 2024-09-20 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer [Phase 3]

See pricing